Prophylaxis, diagnosis and therapy of surgery-related complications in orthopedic and trauma surgery: An observational survey (CHANGE)

European Journal of Trauma

Volumn 31, Issue 2, 2005, Pages 158-167

  Bauersachs, Rupert M ^a   Berger, Karin ^b   Hankowitz, Johannes ^c   Langenberg, Kristian ^c   Marzi, Ingo ^d   Neubauer, Günter ^e   Pauschert, Rolf ^f   Ulle, Tanja ^c   Schramm, Wolfgang ^b  

^a Darmstadt Hospital   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Division Henning   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e Health Economics and Outcomes   (Germany)

^f Spec Clin Conservative O   (Germany)

Author keywords

Enoxaparin; Fondaparinux; Orthopedic surgery; Thrombosis prophylaxis; Trauma surgery

Indexed keywords

ANTICOAGULANT AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANEMIA; BLEEDING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ECHOGRAPHY; EMBOLECTOMY; FEMALE; FEMUR FRACTURE; GASTROINTESTINAL DISEASE; HEMATOMA; HIP FRACTURE; HIP OSTEOARTHRITIS; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; KNEE OSTEOARTHRITIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PERIPHERAL EDEMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBECTOMY; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; TRAUMATOLOGY;

EID: 18544387717     PISSN: 14390590     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00068-005-1442-0     Document Type: Review

References (11)

1. Eriksson BI, Bauer KA, Lassen MR, et al., Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345: 1298-304.
2. Bauer KA, Eriksson BI, Lassen MR, et al., Stering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
3. Lassen MR, Bauer KA, Eriksson NI, et al., the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-20.
4. Turpie AG, Bauer KA, Eriksson BI, et al., for the PENTATHLON Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial. Lancet 2002;359:1721-6.
5. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med 2002;162:1833-40.
6. Eriksson BI, Lassen MR Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med 2003;163:1337-42.
7. Blättler W, Partsch H, Hertel T. Leitlinien zur Diagnostik und Therapie der tiefen Bein-/Beckenvenenthrombose. Phlebologie 1998;27:84-8.
8. Elalamy I, Lecrubier C, Potevin F. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995;74:1383-5.
9. Ahmad S, Jeske WP, Walenga JM. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999;5:259-66.
10. Ver Elst K, Jochmans K, De Pauw A, et al. Plasma D-dimerconcentrations in different clinical conditions. Acta Clin Belg 2002;57:325-30.
11. Bundesgeschäftsstelle Qualitätssicherung GCmbH (BQS). BQS-Qualitätsreport 2002. Düsseldorf: BQS, 2003;96-10.